# The Foster City, California-based firm aims to enhance its oncology pipeline.

*biotech · news · 2026-04-07 · Benzinga*

## Key points

- Gilead will acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestones.
- The Tubulis deal adds TUB-040, an antibody-drug conjugate for ovarian cancer, to Gilead's portfolio.
- Gilead is also acquiring Ouro Medicines for $1.675 billion upfront, expanding its inflammation pipeline.
- Gilead owns 11.5% of Arcellx's outstanding common stock, signaling deeper strategic interests.

**Companies:** Gilead Sciences, Tubulis
**Countries:** United States, Germany

[Read the full story on Benzinga](https://www.benzinga.com/m-a/26/04/51685029/gilead-acquisition-spree-continues-with-3-billion-tubulis-deal)

---

Canonical: https://newsio.io/n/0a8c29de-4023-4bd0-9192-ad173fcc4e9d/the-foster-city-california-based-firm-aims-to-enhance-its-oncology-pipeline-gile
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works